Organization & Developments: CymaBay

Parents

*CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.
2017: Biotech Forum Daily Digest: Revisiting The Rocket Known As CymaBay Therapeutics
2018: CymaBay Makes Progress With Seladelpar_seekingalpha.com
2018: CymaBay Reinforces Its Efforts With Latest Rare Liver Disease Data_seekingalpha.com
2018: CymaBay Rockets On Liver Disease Treatment Seladelpar, Rivaling Intercept's Ocaliva
2018: CymaBay_What Now For This Small Biotech Rocket?_seekingalpha.com
2019: 8 programs to watch in NASH: Four letters and a multibillion-dollar opportunity
2019: CymaBay And Seladelpar In NASH: An Aged Wine Ripe For Success - CymaBay Therapeutics, Inc. (NASDAQ:CBAY)
2019: CymaBay And Seladelpar In NASH: The Moment_seekingalpha.com
2019: CymaBay plummets 75% as it axes liver studies in NASH, PBC
2019: CymaBay Therapeutics Stumbles in NASH Race, Shares Fall
2019: This Biotech (Intercept) Popped After Its Rival Crashed 76% On A Scrapped Test (Cymabay)_www.investors.com
2020: CymaBay Is Clawing Back, Now We Just Need Pipeline Conversion
2021: CymaBay Therapeutics: Checking In On This Roller Coaster Stock
2023: Circling Back On CymaBay Therapeutics_ seekingalpha.com
2023: Why CymaBay, With 159% Growth This Year, Just Surged For A Second Day Running
2024: CymaBay's Seladelpar Is A Solid, But Pricey, Addition To Gilead's Liver Franchise